All In Biotech

Drug Trial Radar · NCT07596290

Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

Efficacy and Safety of Neoadjuvant Short-Course/Long-Course Radiotherapy Combined With Anti-PD-1/CTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

342

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Beijing Friendship HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking University Cancer Hospital & Institute; Peking Union Medical College
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A total of 342 pMMR/MSS LARC patients will be enrolled and randomly assigned in a 1:1:1 ratio to short-course radiotherapy (5×5Gy) followed by sequential dual immunotherapy (paromlimab + tuvonralimab + CAPEOX), long-course radiotherapy followed by sequential dual immunotherapy, or conventional long-course chemoradiotherapy. The primary endpoint is the complete response rate (pCR + cCR). Secondary endpoints include the proportion of patients adopting the "watch-and-wait" strategy, disease-free survival, overall survival, and safety. This study innovatively explores the synergistic mechanism of different radiotherapy fractionations with dual immunotherapy, optimizes the timing of immunotherapy initiation, and constructs a clinical-imaging-pathology multimodal efficacy prediction model, aiming to advance LARC treatment from empirical to precision therapy while achieving organ and function preservation.

Conditions

  • Locally Advanced Rectal Adenocarcinoma
  • Neoadjuvant Chemoradiation
  • Neoadjuvant Immunotherapy

Interventions

  • Short-course radiotherapyRadiation

    Arm A receive short-course radiotherapy

  • Long-course radiotherapyRadiation

    Arm B and C will receive long-course radiotherapy

  • ImmunotherapyDrug

    Anti-PD-1/CTLA-4 Dual Immunotherapy (paromlimab and Tuvonralimab)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete responseTime frame: 3 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.